Gainers

• Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session.
• American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their outstanding shares is at $179.2 million. The company's, Q2 earnings came out today.
• Precigen (NASDAQ:PGEN) stock moved upwards by 11.63% to $7.29. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q2 earnings report came out today.
• Travere Therapeutics (NASDAQ:TVTX) shares rose 10.67% to $62.0. The market value of their outstanding shares is at $5.1 billion. The company's, Q2 earnings came out today.
• Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 7.81% to $1.24. The company's market cap stands at $85.2 million.
• Rigel Pharmaceuticals (NASDAQ:RIGL) shares moved upwards by 7.23% to $41.5. The company's market cap stands at $692.5 million. The company's, Q2 earnings came out today.

Losers

• China SXT Pharmaceuticals (NASDAQ:SXTC) stock decreased by 31.8% to $0.08 during Tuesday's after-market session. The market value of their outstanding shares is at $2.9 million.
• Vivos Therapeutics (NASDAQ:VVOS) shares fell 25.82% to $0.34. The market value of their outstanding shares is at $5.8 million.
• LeMaitre Vascular (NASDAQ:LMAT) stock decreased by 13.84% to $91.15. The market value of their outstanding shares is at $2.3 billion. The company's, Q2 earnings came out today.
• Adagio Medical Holdings (NASDAQ:ADGM) stock fell 13.6% to $0.69. The company's market cap stands at $10.2 million.
• GlucoTrack (NASDAQ:GCTK) shares decreased by 13.3% to $0.52. The company's market cap stands at $3.2 million.
• Autonomix Medical (NASDAQ:AMIX) stock decreased by 11.54% to $17.25. The market value of their outstanding shares is at $1.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.